AcelRx Pharmaceuticals, Inc. — FY2016 Form 10-K
Entity note: The supplied filing is for AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), not TALPHERA, INC. It covers the fiscal year ended December 31, 2016; Q4 figures are included where reported. Amounts below are in U.S. dollars.
Business context and reporting period
AcelRx is a clinical-stage specialty pharmaceutical company developing sublingual sufentanil therapies for acute pain. Its lead candidate, DSUVIA (ARX-04 outside the U.S.), is a single-dose tablet administered by a healthcare professional; ZALVISO is a patient-controlled hospital system. ZALVISO had European approval and early commercial launches, but neither product had FDA approval as of the filing.
Financial performance and liquidity
- FY2016 revenue: $17.4 million, down from $19.3 million in 2015. This comprised $6.4 million of collaboration revenue and $10.9 million under the Department of Defense (DoD) contract.
- FY2016 net loss: $43.2 million, versus $24.4 million in 2015; basic loss per share was $0.95 versus $0.55. Operating loss was $32.0 million versus $20.0 million.
- Costs: Operating expenses were $49.3 million, including $12.3 million cost of goods sold, $21.4 million R&D and $15.6 million G&A. AcelRx reported negative gross margins on ZALVISO supplied to Grünenthal; 2016 direct manufacturing costs were $6.4 million and indirect manufacturing costs were $5.9 million, against $5.7 million of product sales.
- Cash flow: Operating activities used $29.4 million, compared with $20.0 million in 2015. Investing activities provided $1.8 million; financing activities used $0.03 million. Cash and cash equivalents were $80.3 million at year-end, down from $107.9 million; working capital was $78.9 million.
- Debt and other obligations: Year-end long-term debt was $21.5 million. The liability recorded for the PDL future-royalty sale was $73.0 million; the arrangement caps PDL receipts at approximately $195.0 million. Stockholders’ equity was negative $5.3 million.
- Q4 2016: Revenue was $6.4 million and net loss was $9.7 million, compared with Q4 2015 revenue of $1.7 million and net loss of $10.5 million.
Material changes versus prior year
- Revenue declined 9.9% year over year as lower collaboration revenue more than offset increased DoD reimbursements. ZALVISO product sales began in 2016; royalties were minimal.
- Net loss increased by $18.8 million. The main notable item was non-cash interest expense on the PDL royalty liability, which rose to $9.4 million from $2.4 million. Operating expenses also increased overall, particularly cost of goods sold, while R&D expense decreased modestly.
- Operating cash use increased by $9.4 million, and year-end cash and cash equivalents fell by $27.6 million. The 2015 comparison included $61.2 million of net proceeds from the royalty monetization; there were no comparable royalty-sale proceeds in 2016.
- At year-end 2016, the company had not drawn on its $40 million at-the-market equity sales program. The filing says the company expected existing capital resources to support operations through at least Q1 2018.
Outlook, risks and unusual items
- The FDA accepted the DSUVIA NDA for filing, with an October 12, 2017 PDUFA goal date. AcelRx planned an EU MAA submission for ARX-04 in the first half of 2017; additional controlled emergency-department or comparator studies might be required.
- ZALVISO’s U.S. NDA had received a Complete Response Letter concerning device performance, inadvertent dosing and shelf life. The company initiated the approximately 315-patient IAP312 study in September 2016, expected completion in mid-2017 and planned NDA resubmission by year-end 2017, subject to results and FDA requirements.
- Grünenthal had launched ZALVISO in Germany, France, the U.K. and Italy, but launches were early and sales limited. Cartridge deliveries were behind schedule, and reported controller setup issues had prompted additional training and revised software. AcelRx expected 2017 royalties to be minimal.
- The company relied on contract manufacturers and single-source supply in important areas. Delays or quality issues could affect clinical programs, ZALVISO supply and a potential DSUVIA launch. ZALVISO transfer prices and current production economics were expected to produce negative gross margins for the foreseeable future.
- AcelRx reported recurring losses and negative operating cash flow and stated it would need additional capital beyond its then-expected runway. Risks include regulatory delays or rejection, funding availability and dilution, limited reimbursement or market uptake, opioid-related safety and REMS requirements, competition, and manufacturing execution.
- Subsequent event: On March 2, 2017, AcelRx refinanced its Hercules debt. It borrowed approximately $20.5 million to repay the prior facility; up to an additional $10 million was contingent on DSUVIA approval and lender committee approval. The new loan carried an interest rate of at least 9.55%, was secured by substantially all assets other than intellectual property, and had a scheduled March 2020 maturity.
- The independent auditor issued unqualified opinions on the financial statements and internal control over financial reporting. Management also concluded disclosure controls were effective as of December 31, 2016.
Most important facts for investors to verify
- Whether DSUVIA received FDA approval by the PDUFA date and what label, restrictions or REMS requirements applied.
- IAP312 results, FDA feedback and the timing and outcome of any ZALVISO NDA resubmission.
- Actual cash burn and runway compared with management’s Q1 2018 estimate, including subsequent financing, debt service and any equity issuance.
- Whether manufacturing delays and device issues were resolved, and their effects on Grünenthal launches, product sales and margins.
- Commercial uptake and reimbursement for ZALVISO, alongside the royalties and milestones retained by AcelRx after the PDL transaction.
- Any additional clinical requirements for an EU ARX-04 application, particularly for trauma-related pain and reimbursement support.